In melanoma patients who qualified for PD-1-targeted therapy, low pre-treatment expression levels of BiP were significantly associated with prolonged OS (P = 0.008, n = 12 patients) and disease-free survival (P < 0.021, n = 9) (86). This evidence concerns the gene PDCD1 and melanoma.